CancerDMU-CHNCT07501871
Investigation of Digital Media Use in Patients Receiving Chemotherapy
An observational study of Cancer and Chemotherapy, run by Fenerbahce University at 1 site in Turkey (Türkiye).
Trial summary
This study aims to examine digital media use and eHealth literacy among patients receiving chemotherapy. Digital media has become an important tool for accessing health information, communicating with healthcare providers, and supporting self-management. Read more about this study
- Who is it for?
- Ages 18 to 67 years
- Conditions the study is for
- Cancer, Chemotherapy
- How many people
- 80 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 20 Apr 2026to 20 May 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 67 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients aged between 18 and 67 years receiving chemotherapy treatment in an outpatient setting will be included in the study. Participants will be selected according to the inclusion and exclusion criteria and will voluntarily agree to participate.
Who may be able to join
- Patients aged between 18 and 67 years
- Receiving chemotherapy treatment
- Able to communicate and understand the study procedures
- Voluntarily agree to participate in the study
Who cannot join
- Patients with cognitive impairment or communication difficulties
- Patients who refuse to participate
- Patients with incomplete questionnaire responses
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
Acıbadem University Atakent Hospital
Istanbul, Küçükçekmece
About this study
Official title: Assessment of Digital Meda Use and eHealth Literacy in Patients Receiving Chemotherapy
This study aims to examine digital media use and eHealth literacy among patients receiving chemotherapy. Digital media has become an important tool for accessing health information, communicating with healthcare providers, and supporting self-management.
This observational study will be conducted with adult patients receiving chemotherapy in an outpatient setting. Data will be collected using a sociodemographic information form and the eHealth Literacy Scale (eHEALS). The findings are expected to contribute to a better understanding of digital media use and digital health literacy levels in chemotherapy patients.
Read the detailed description
Cancer is a major global health problem, and chemotherapy is one of the most commonly used treatment methods. With the increasing use of digital media, patients frequently access health-related information, communicate with healthcare providers, and engage in self-management. Digital health literacy plays a key role in this process.
This study aims to describe digital media use and eHealth literacy levels among patients receiving chemotherapy. It will also explore the relationship between digital media use and selected patient characteristics.
The study will be conducted as a descriptive, cross-sectional observational study in an outpatient chemotherapy setting. Data will be collected using a sociodemographic information form and the eHealth Literacy Scale (eHEALS).
- Conditions
- Cancer, Chemotherapy
- Being tested
- No Intervention (Observational Study)
- Keywords
- Oncology Nursing, Digital Media, eHealth Literacy
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No Intervention (Observational Study)Other
This is an observational study with no assigned intervention. Data will be collected through surveys assessing digital media use and eHealth literacy.
| Study group | Role | What they receive |
|---|---|---|
| Chemotherapy Patients | Patients receiving chemotherapy whose digital media use and eHealth literacy are assessed. Receives: Other: No Intervention (Observational Study) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Digital Media Use Level
Digital media use will be evaluated based on frequency, duration, and purpose of use through a structured questionnaire.
Measured: At baseline (during chemotherapy treatment)
Secondary outcomes (1)
eHealth Literacy Level
eHealth literacy will be assessed using the eHealth Literac Scale (eHEALS)
Measured: At baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Mar 2026
- Study start20 Apr 2026 (estimated)
- Primary completion20 May 2026 (estimated)
- Study completion20 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by Fenerbahce UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fenerbahce University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Emine I Yıldız, Fenerbahce University
- Investigators
- Emine Ilayda Yildiz, Principal investigator, Fenerbahce University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07501871
- Sponsor's protocol ID
- ASG-YILDIZ-002
- Acronym
- DMU-CH
- Status last verified
- Apr 2026
- First submitted
- 24 Mar 2026
- Last updated
- 21 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Digital Meda Use and eHealth Literacy in Patients Receiving Chemotherapy
- ClinicalTrials.gov ID
- NCT07501871
- Acronym / sponsor ID
- DMU-CH / ASG-YILDIZ-002
- Conditions
- Cancer, Chemotherapy
- Keywords
- Oncology Nursing, Digital Media, eHealth Literacy
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Fenerbahce UniversityUniversity, hospital or other
- Study start
- 20 Apr 2026 (estimated)
- Primary completion
- 20 May 2026 (estimated)
- Study completion
- 20 May 2026 (estimated)
- First posted
- 30 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to examine digital media use and eHealth literacy among patients receiving chemotherapy. Digital media has become an important tool for accessing health information, communicating with healthcare providers, and supporting self-management.
This observational study will be conducted with adult patients receiving chemotherapy in an outpatient setting. Data will be collected using a sociodemographic information form and the eHealth Literacy Scale (eHEALS). The findings are expected to contribute to a better understanding of digital media use and digital health literacy levels in chemotherapy patients.
Detailed description
Cancer is a major global health problem, and chemotherapy is one of the most commonly used treatment methods. With the increasing use of digital media, patients frequently access health-related information, communicate with healthcare providers, and engage in self-management. Digital health literacy plays a key role in this process.
This study aims to describe digital media use and eHealth literacy levels among patients receiving chemotherapy. It will also explore the relationship between digital media use and selected patient characteristics.
The study will be conducted as a descriptive, cross-sectional observational study in an outpatient chemotherapy setting. Data will be collected using a sociodemographic information form and the eHealth Literacy Scale (eHEALS).
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Chemotherapy Patients | – | Other: No Intervention (Observational Study)Patients receiving chemotherapy whose digital media use and eHealth literacy are assessed. |
Who may qualify
- Ages
- 18 to 67 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients aged between 18 and 67 years receiving chemotherapy treatment in an outpatient setting will be included in the study. Participants will be selected according to the inclusion and exclusion criteria and will voluntarily agree to participate.
Key inclusion criteria (4 listed)
- Patients aged between 18 and 67 years
- Receiving chemotherapy treatment
- Able to communicate and understand the study procedures
- Voluntarily agree to participate in the study
Key exclusion criteria (3 listed)
- Patients with cognitive impairment or communication difficulties
- Patients who refuse to participate
- Patients with incomplete questionnaire responses
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No Intervention (Observational Study)This is an observational study with no assigned intervention. Data will be collected through surveys assessing digital media use and eHealth literacy. | Other | Chemotherapy Patients |
Primary outcome
Digital Media Use Level
Time frame: At baseline (during chemotherapy treatment)
Digital media use will be evaluated based on frequency, duration, and purpose of use through a structured questionnaire.
1 secondary outcome
eHealth Literacy Level
Time frame: At baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Emine Ilayda Yildiz principal investigator
Fenerbahce University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer and Chemotherapy, run by Fenerbahce University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Emine Ilayda Yildiz, RN (+905436411944, emineeilaydaa@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Digital Media Use Level (time frame: At baseline (during chemotherapy treatment)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2026; AzTrials last refreshed its copy on 8 Nov 2026.